This study is not yet accepting patients
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma, Carcinoma, Transitional Cell Carcinoma, Durvalumab, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab, Vactosertib+Durvalumab
Lead Scientist at UCSF
- Lawrence Fong, MD
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.
- not yet accepting patients
- Start Date
- Completion Date
- MedPacto, Inc.
- Phase 2 research study
- Study Type
- Expecting 48 study participants
- Last Updated